Abstract
To evaluate the metabolic effects of long-term treatment with recombinant human (rh) GH in short children with chronic renal failure (CRF), annual oral glucose tolerance tests (oGTT) during rhGH therapy for up to 5 y in 53 prepubertal children with CRF on conservative treatment, dialysis, and after renal transplantation were compared with that of 12 age-matched children treated with rhGH for idiopathic short stature. At the start of rhGH treatment, fasting values of glucose, insulin, glycosylated Hb A(HbA1C), triglycerides, cholesterol, glucose, and insulin responses during oGTT were significantly elevated in all patient groups compared with control subjects (p < 0.001). In the total population, fasting and 2-h postprandial glucose concentrations were inversely correlated with GFR and positively with age and methylprednisolone dosage in transplanted patients. Fasting insulin levels were positively correlated with body mass index and inversely with GFR. RhGH treatment was not associated with a change in fasting or stimulated glucose concentrations in any treatment group throughout the observation period. In contrast, serum insulin levels increased during the first treatment year in all groups, resulting in a more marked elevation of integrated insulin levels in transplant (1402 ± 179 pM) and dialysis (1025 ± 114 pM) patients compared with conservatively treated patients (829 ± 94 pM), and control subjects (719 ± 89 pM) (p < 0.01). Hyperinsulinemia persisted in all treatment groups for up to 5 y of follow-up. In conclusion, age, renal function, and obesity are the major independent predictors of glucose tolerance in children with CRF. Long-term rhGH treatment does not affect glucose tolerance, but aggravates the preexisting hyperinsulinemia in children with end-stage renal disease. In concert with the dyslipidemia of uremia, the rhGH-promoted hyperinsulinemia may contribute to the long-term risk for premature atherosclerosis in patients with childhood onset CRF.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
Abbreviations
- BMI:
-
body mass index
- CRF:
-
chronic renal failure
- oGTT:
-
oral glucose tolerance test
- ΔI30/ΔG30:
-
change in insulin/glucose ratio over the first 30 min of oGTT
- SDS:
-
SD score
- rhGH:
-
recombinant human GH
References
Koch VH, Lippe BM, Nelson PA, Boechat MI, Sherman BM, Fine RN 1989 Accelerated growth after recombinant human growth hormone treatment of children with chronic renal failure. J Pediatr 115: 365–371.
Tönshoff B, Mehls O, Heinrich U, Blum WF, Ranke MB, Schauer A 1990 Growth-stimulating effects of recombinant human growth hormone in children with end-stage renal disease. J Pediatr 116: 561–566.
Rees L, Rigden SPA, Ward G, Preece MA 1990 Treatment of short stature in renal disease with recombinant human growth hormone. Arch Dis Child 65: 856–860.
Fine RN, Kohaut EC, Brown D, Perlman AJ, For The Genentech Cooperative Study Group 1994 Growth after recombinant human growth hormone treatment in children with chronic renal failure: report of a multicenter randomized double blind placebo-controlled study. J Pediatr 124: 374–382.
Haffner D, Wühl E, Tönshoff B, Mehls O, for the German Study Group for Growth Hormone Treatment in Chronic Renal Failure 1994 Growth hormone (GH) treatment in short children with chronic renal failure(CRF): 5-year experience. Nephrol Dial Transplant 9: 960–961.
Fine RN, Kohaut E, Brown D, Kuntze J, Attie KM 1996 Long-term treatment of growth retarded children with chronic renal insufficiency, with recombinant human growth hormone. Kidney Int 49: 781–785.
Van Es A 1991 Growth hormone treatment in short children with chronic renal failure and after renal transplantation: combined data from European clinical trials. Acta Paediatr Scand Suppl 379: 42–48.
Tönshoff B, Haffner D, Mehls O, Dietz M, Ruder H, Blum W F, Heinrich U, Stoever B, Members of the German Study Group for GH Treatment in Children with Renal Allografts 1993 Efficacy and safety of growth hormone treatment in short children with renal allografts: three year experience. Kidney Int 44: 199–207.
Hokken-Koelega ACS, Stijnen T, De J, Donckerwolke RA, Groothoff JW, Wolff ED, Blum WF, de Muinck Keizer-Schrama SMPF, Drop SLS 1996 A placebo controlled double blind trial of growth hormone treatment in prepubertal children after renal transplant. Kidney Int 49 ( suppl 53): 128–134.
Schaefer F, Mehls O 1994 Endocrine, metabolic and growth disorders. In: Holliday MA, Barrat TM, Avner ED (eds) Pediatric Nephrology. Williams & Wilkins, Baltimore, pp 1241–1286.
Mak RHK, Haycock GB, Chantler C 1983 Glucose intolerance in children with chronic renal failure. Kidney Int 24 ( suppl 15): 22–26.
Smith D, DeFronzo RA 1982 Insulin resistance in uremia is mediated by postbinding defects. Kidney Int 22: 54–62.
Rosenfeld RG, Wilson DM, Dollar LA, Bennet A, Hintz RL 1982 Both human pituitary growth hormone and recombinant DNA derived human growth hormone cause insulin-resistance at a postreceptor level. J Clin Endocrinol Metab 55: 973–981.
Bratusch-Marrain RR, Smith D, DeFronzo RA 1982 The effect of growth hormone on glucose metabolism and insulin secretion in man. J Clin Endocrinol Metab 54: 1033–1038.
Fennel RS, Van Deusen J, Riley WL 1983 Steroid-induced diabetes in pediatric renal transplant recipients. In J Pediatr Nephrol 4: 103–107.
Amiel SA, Sherwin RS, Simonson DC, Lauritano AA, Tamborlane WV 1986 Impaired insulin action in puberty. N Engl J Med 315: 215–219.
Deschamps I, Giron BJ, Lestradet H 1977 Blood glucose, insulin, and free fatty acid levels during oral glucose tolerance tests in 158 obese children. Diabetes 26: 89–93.
Tönshoff B, Dietz M, Haffner D, Tönshoff C, Stöver B, Mehls O, and Members of the German Study Group for Growth Hormone Treatment in Chronic Renal Failure 1991 Effects of 2 years of growth hormone treatment in short children with renal disease. Acta Paediatr Scand Suppl 379: 33–41.
Prader A, Largo RH, Molinari L, Issler C 1988 Physical growth of Swiss children from birth to 20 years of age. Helv Paediatr Acta Suppl 52: 1–125.
Rolland-Cachera MF, Cole TJ, Sempe M, Tichet J, Rossignol C, Charraud A 1991 Body mass index variations: centiles from birth to 87 years. Eur J Clin Nutr 45: 13–21.
Tanner JM, Whitehouse RH, Cameron N, Marshall WA, Healy MJR, Goldstein H 1983 Assessment of Skeletal Maturity and Prediction of Adult Height (TW2 Method), 2nd Ed. Academic Press, New York, pp 50–103.
Friedman S, Humbert JR 1979 A simple microchromatographic column for determination of hemoglobin A1a+b and A1c . Hemoglobin 3: 411–428.
Schwartz GJ, Haycock GB, Edelman CM 1976 A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 58: 259–263.
Haffner SM, Stern MP, Hazuda HP, Pugh JA, Patterson JK 1986 Hyperinsulinemia in a population at high risk for non-insulin dependent diabetes mellitus. N Engl J Med 315: 220–224.
National Diabetes Data Group 1979 Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28: 1039–1057.
Haffner SM, Miettinen H, Gaskill SP, Stern MP 1995 Decreased insulin secretion and increased insulin resistance are independently related to the 7-year risk of NIDDM in Mexican-Americans. Diabetes 44: 1386–1391.
Tönshoff B, Tönshoff C, Mehls O, Pinkowski J, Blum WF, Heinrich U, Stöver B, Gretz N 1992 Growth hormone treatment over one year in children with preterminal chronic renal failure: no adverse effect on glomerular filtration rate. Eur J Pediatr 151: 601–607.
Van Dop C, Donohoue PA, Jabs KL, Bock GH, Fivush BA, Harmon WE 1991 Glucose tolerance in children with renal allografts and effect of growth hormone treatment. J Pediatr 118: 708–714.
Saenger P, Attie KM, DiMartino-Nardi J, Fine RN, The Genentech Collaborative Group 1996 Carbohydrate metabolism in children receiving growth hormone for five years. Pediatr Nephrol 10: 261–263.
Schmitz O 1985 Insulin mediated glucose uptake in non-dialyzed and dialyzed uremic insulin-dependent diabetic subjects. Diabetes 34: 1152–1159.
Schmitz O 1991 Glucose metabolism in non-diabetic and insulin-dependent diabetic subjects with end-stage renal failure. Dan Med Bull 38: 36–52.
Sobel BE 1996 Potentiation of vasculopathy by insulin. Implications from an NHLBI clinical alert. Circulation 93: 1613–1615.
Perry IJ, Wannamethee SG, Whincup PH, Shaper AG, Walker MK, Alberti KG 1996 Serum insulin and incident coronary heart disease in middle-aged British men. Am J Epideminol 144: 224–234.
Marongiu F, Conti M, Mameli G, Sorano GG, Cossu E, Cirillo R, Balestrieri A 1990 Is the imbalance between thrombin and plasmin activity in diabetes related to the behavior of antiplasmin activity?. Thromb Res 58: 91–99.
McGill JB, Schneider DJ, Arfken CL, Lucore CL, Sobel BE 1994 Factors responsible for impaired fibrinolysis in obese patients and NIDDM patients. Diabetes 43: 104–109.
Nordt TK, Sawa H, Fujiii S, Sobel BE 1995 Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulinin vivo. Circulation 91: 764–770.
Cressman MD, Heyka RJ, Paganini EP, O'Neil J, Sibinski CI, Hoff HF 1992 Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 86: 475–482.
Querfeld U, Haffner D, Wühl E, Wingen AM, Wolter K, Friedrich B, Michalk DV, Mehls O 1996 Treatment with growth hormone increases lipoprotein(a) serum levels in children with chronic renal insufficiency. Eur J Pediatr 155: 913–918.
Sonksen PH, Greenwood FC, Ellis JP, Lowy C, Rutherford A, Nabarro JDN 1967 Changes of carbohydrate tolerance in acromegaly with progress of the disease and in response to treatment. J Clin Endocrinol Metab 27: 1418–1423.
Rizza RA, Mandarino JL, Gerich JE 1982 Effects of growth hormone on insulin action in man. Mechanisms of insulin resistance, impaired suppression of glucose production, and impaired stimulation of glucose utilization. Diabetes 31: 663–669.
Formby B, Ullrich A, Coussens L, Walker L, Petersen CM 1982 Growth hormone stimulates insulin gene expression in cultured human fetal pancreatic islet. J Clin Endocrinol Metab 66: 1075–1080.
Rabinovitch A, Quigley C, Rechler MM 1983 Growth hormone stimulates islet B-cell replication in neonatal rat pancreatic monolayer cultures. Diabetes 32: 307–312.
Walker J, Chaussain JL, Bougneres PF 1989 Growth hormone treatment of children with short stature increases insulin secretion but does not impair glucose disposal. J Clin Endocrinol Metab 69: 253–258.
Acknowledgements
RhGH was kindly provided by Pharmacia and Upjohn, Stockholm, Sweden (CRF patients) and Novo Nordisc A/S, Denmark(control subjects). We are indebted to Dr. Gudrun Cimander, Pharmacia and Upjohn, Erlangen, Germany, for valuable assistance in coordinating the study.
Author information
Authors and Affiliations
Consortia
Rights and permissions
About this article
Cite this article
Haffner, D., Nissel, R., Wühl, E. et al. Metabolic Effects of Long-Term Growth Hormone Treatment in Prepubertal Children with Chronic Renal Failure and after Kidney Transplantation. Pediatr Res 43, 209–215 (1998). https://doi.org/10.1203/00006450-199802000-00009
Received:
Accepted:
Issue date:
DOI: https://doi.org/10.1203/00006450-199802000-00009
This article is cited by
-
Clinical practice recommendations for growth hormone treatment in children with chronic kidney disease
Nature Reviews Nephrology (2019)
-
Growth hormone therapy in children with CKD after more than two decades of practice
Pediatric Nephrology (2016)
-
New-onset diabetes after kidney transplant in children
Pediatric Nephrology (2015)
